New study identifies drugs that are safe to use in COVID-19 treatment
The study also found that other types of drugs – such as TNF blockers and JAK inhibitors – are also safe to use in the treatment of COVID-19.
The researchers analysed 89 existing studies on other coronaviruses such as MERS and SARS as well as the limited literature on COVID-19, to determine if certain pain medications, steroids and other drugs used by people already suffering from a disease should be avoided if they contract COVID-19.
The study comes following speculation over the use of certain non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, to treat COVID-19, with some saying these drugs can actually make the condition worse.
Earlier this month, French authorities criticised the use of certain anti-inflammatories – namely ibuprofen and cortisone – to treat the novel coronavirus disease.
They warned that widely used over-the-counter anti-inflammatories may actually worsen the infection, adding that patients should opt for paracetamol if they experience a fever instead.
The European Medicines Agency also responded to these reports, and advised that while there is no scientific evidence that drugs like ibuprofen worsen COVID-19, it is closely monitoring the situation.
Certain individuals – such as cancer patients – may already be taking immunosuppressive drugs, which lowers the body’s immune system, or immunostimulant drugs which work to boost the immune system. Healthcare professionals need, therefore, to know which drugs should be stopped if a patient catches COVID-19.
“This pandemic has led to challenging decision-making about the treatment of COVID-19 patients who were already critically unwell,” said Mieke Van Hemelrijck, a cancer epidemiologist at KCL and an author on the paper.
“In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication,” she added.
The study also found that low doses of prednisolone or tacrolimus therapy could be helpful in the treatment of COVID-19.
“Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections. However further investigation is needed,” said Sophia Papa, a medical oncologist and immunologist at KCL and co-author of the study.
2026-08-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Nanobody preparation tips sharing
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
China's original 'non-invasive' surgical equipment is exported to Colombia for clinical treatment and research in the country
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
Recommend Reading
-
French Cosmetics Exports Poised for First Drop in Over Two Decades in 2025
-
Libya’s Largest Refinery Faces Full Shutdown After Five Rounds of Airstrikes
-
SIBUR’s Massive Siberian Petrochemical Complex Shuts After Drone Attack, LPG Supply Disrupted
-
Behind Arkema’s ¥430 Million Claim: A Patent War Over Acrylic Acid Is Tearing Off the “Technical Fig Leaf” of China’s Chemical Giants
-
Arkema Invests $60 Million to Upgrade its US FluoroSpecialties Production Unit
-
Palm Oil Prices in January Steadily Rise
-
August Aniline Market Stabilizes After Fluctuations in China
-
August Butadiene Rubber Market Prices Slightly Increased in China
-
Lacking Positive Support, Cyclohexane Mainly Remains Stable
-
Ethylene Glycol Prices Ease Slightly on August 28